Xeris Biopharma Holdings, Inc. (XERS)
Automate Your Wheel Strategy on XERS
With Tiblio's Option Bot, you can configure your own wheel strategy including XERS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XERS
- Rev/Share 1.4599
- Book/Share -0.2304
- PB -19.876
- Debt/Equity -7.6506
- CurrentRatio 1.7197
- ROIC -0.0892
- MktCap 733509900.0
- FreeCF/Share -0.1799
- PFCF -26.7451
- PE -15.4894
- Debt/Assets 0.852
- DivYield 0
- ROE 1.6048
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing
Published: June 18, 2025 by: Seeking Alpha
Sentiment: Positive
Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company's revenue is expected to grow significantly by 2030, the stock price may rise accordingly. Moreover, XP-8121 may serve as a catalyst for higher stock valuation.
Read More
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. “We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achi.
Read More
Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Eason Lee - Leerink Partners Jason Dorr - Oppenheimer Chase Knickerbocker - Craig-Hallum Operator Good morning. Thank you for attending today's Xeris Biopharma First Quarter 2025 Results Conference Call.
Read More
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago.
Read More
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. “We're very pleased with our strong start to the year, delivering another quarter of outstanding revenue growth,” said John Shannon, Xe.
Read More
Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Negative
Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include Gvoke and Recorlev revenues, EPS, adjusted EBITDA, and cash flow, as these will determine Xeris's path to profitability. Risks include potential underperformance in product revenue, rising SG&A expenses, and any delays in pipeline programs like XP-8121.
Read More
Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript
Published: March 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies David Amsellem - Piper Sandler Leland Gershell - Oppenheimer Mazahir Alimohamed - Leerink Partners Operator Good morning, and welcome to the Xeris Biopharma Fourth Quarter and Full Year 2024 Financial Results.
Read More
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago.
Read More
About Xeris Biopharma Holdings, Inc. (XERS)
- IPO Date 2018-06-21
- Website https://www.xerispharma.com
- Industry Biotechnology
- CEO Mr. John P. Shannon
- Employees 394